Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1954 1
1956 3
1957 1
1959 2
1960 2
1961 4
1962 2
1963 1
1964 2
1965 1
1966 3
1967 2
1968 1
1969 1
1970 3
1971 2
1972 2
1973 2
1974 2
1975 1
1976 2
1978 2
1979 2
1980 6
1981 3
1982 2
1983 5
1984 5
1985 1
1986 4
1987 1
1988 3
1989 4
1990 2
1991 7
1992 6
1993 3
1994 3
1995 2
1996 1
1997 1
1998 3
1999 2
2000 2
2002 2
2004 2
2005 2
2006 4
2007 3
2008 2
2009 5
2010 3
2011 3
2012 9
2013 8
2014 6
2015 11
2016 10
2017 8
2018 6
2019 5
2020 6
2021 11
2022 10
2023 10
2024 7
2025 15
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

235 results

Results by year

Filters applied: . Clear all
Page 1
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Louis E, et al. JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414. JAMA. 2024. PMID: 39037800 Free PMC article. Clinical Trial.
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C; UNIFI Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750. N Engl J Med. 2019. PMID: 31553833 Free article. Clinical Trial.
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group. Sandborn WJ, et al. N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617. N Engl J Med. 2021. PMID: 34587385 Clinical Trial.
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravata I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Peyrin-Biroulet L; STARDUST study group. Danese S, et al. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):294-306. doi: 10.1016/S2468-1253(21)00474-X. Epub 2022 Feb 1. Lancet Gastroenterol Hepatol. 2022. PMID: 35120656 Clinical Trial.
[Lymphangiomyomatosis syndrome].
Ardichvili D, Colard M, de Windt J. Ardichvili D, et al. Ann Anat Pathol (Paris). 1970 Jul-Sep;15(3):307-20. Ann Anat Pathol (Paris). 1970. PMID: 5504425 French. No abstract available.
Genome sequencing for the diagnosis of intellectual disability as a paradigm for rare diseases in the French healthcare setting: the prospective DEFIDIAG study.
El Chehadeh S, Heide S, Quélin C, Rio M, Margot H, Geneviève D, Isidor B, Goldenberg A, Guégan C, Lesca G, Willems M, Ormières C, Caumes R, Busa T, Bonneau D, Guerrot AM, Marey I, Vera G, Marzin P, Philippe A, Garde A, Coubes C, Vincent M, Michaud V, Mignot C, Charles P, Sigaudy S, Edery P, Lacombe D, Boland A, Nowak F, Bouctot M, Humbert-Asensio ML, Simon A, Chennen K, Sabour N, Delmas C, Nicolas G, Saugier-Veber P, Lecoquierre F, Cassinari K, Keren B, Courtin T, De Sainte Agathe JM, Malan V, Barcia G, Tran Mau-Them F, Safraou H, Philippe C, Thévenon J, Chatron N, Januel L, Piton A, Haushalter V, Gérard B, Lejeune C, Faivre L, Sanlaville D, Héron D, Odent S, Nitschké P, Schluth-Bolard C, Lyonnet S, Deleuze JF, Binquet C, Dollfus H; DEFIDIAG study group. El Chehadeh S, et al. Genome Med. 2025 Oct 3;17(1):110. doi: 10.1186/s13073-025-01527-4. Genome Med. 2025. PMID: 41044778 Free PMC article.
Oxidant-induced arachidonic acid release and impairment of fatty acid acylation in vascular smooth muscle cells.
Cane A, Breton M, Koumanov K, Béréziat G, Colard O. Cane A, et al. Am J Physiol. 1998 Apr;274(4):C1040-6. doi: 10.1152/ajpcell.1998.274.4.C1040. Am J Physiol. 1998. PMID: 9575801
Identical kinetics of inhibition of AA incorporation and AA release were observed after cell treatment with AlF4-, a process not involving phospholipase A2 (PLA2) activation as recently described (A. Cane, M. Breton, G. Bereziat, and O. Colard. Biochem. Pharmacol. 53: 327- …
Identical kinetics of inhibition of AA incorporation and AA release were observed after cell treatment with AlF4-, a process not involving p …
235 results